Loading...

FITC Annexin V

Pricing & Availability
Regulatory Status
RUO
Other Names
Annexin A5, Dead, Apoptosis
Ave. Rating
Submit a Review
Product Citations
publications
AnnexinV_FITC_092908.jpg
Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • AnnexinV_FITC_092908.jpg
    Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • B_AnnexinV_FITC_092908.jpg
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
640905 25 tests 83 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640906 100 tests 194 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640945 300 tests 405 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer (cat. no. 422201) is recommended for use with Annexin V staining.Annexin V binding alone cannot differentiate between apoptotic cells and necrotic. Therefore, we recommend using our Helix NP™ Blue (Cat. No. 425305), Helix NP™ Green (Cat.  No. 425303) or Helix NP™ NIR (Cat. No. 425301). Early apoptotic cells will exclude 7-AAD and PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat
Reported Reactivity
Other Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The purified protein was conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The Annexin V solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per 100,000 - million cells in a 100 µl volume of Annexin V Binding Buffer (Cat No. 422201). It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Annexin V Staining

  1. Wash cells twice with cold BioLegend Cell Staining Buffer (Cat. No. 420201) and then resuspend cells in Annexin V Binding Buffer (Cat. No. 422201) at a concentration of 1x106 cells/mL.
  2. Transfer 100 µL of cell suspension in 5 mL test tube.
  3. Add 5 µL of fluorochrome conjugated Annexin V.
  4. Stain with a viability dye, such as PI (Cat. No. 421301), 7-AAD (Cat. Nos. 420403 & 420404), or Helix NP dyes (Cat. Nos. 425301, 425303, & 425305), if desired.
  5. Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark.
  6. Add 400* µL of Annexin V Binding Buffer (Cat. No. 422201) to each tube. *For more concentrated samples, add a minimum of 200 µl of Annexin V Binding Buffer in this step.
  7. Analyze by flow cytometry.

For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References

(PubMed link indicates BioLegend citation)
  1. Koopman G, et al. 1994. Blood 84:1415.
  2. Vermes I, et al. 1995. J. Immunol. Methods 184:39.
  3. Dachary-Prigent J, et al. 1993. Blood 81:2554.
  4. Sekine C, et al. 2009. Int Immunol. PubMed
  5. Grujic M, et al. 2010. J. Immunol. 185:1730. PubMed
  6. Mulik RS, et al. 2010. Int J Pharm. 398:190. PubMed
  7. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  8. Speth C,et al. 2013. J Infect Dis. 207:823. PubMed
  9. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  10. Gill K, et al. 2013. Biocheim Biophys Acta. 830:2763. PubMed
  11. Juel HB, et al. 2013. PLoS One. 8:64619. PubMed
  12. Hellmann J, et al. 2013. J. Immunol. 191:1383. PubMed
  13. Sequier S, et al. 2013. PLoS One. 8:70937. PubMed
  14. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  15. Chen YL, et al. 2013. J Exp Med. PubMed
  16. Lin WH, et al. 2014. PLoS One. 9:83160. PubMed
  17. Salge-Bartles U, 2014. Thromb res. 133:244. PubMed
  18. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  19. Intermann J, et al. 2014. Cell Signal. 26:1567. PubMed
  20. de Vires M, 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  21. M Parrula MC, et al. 2014. Virus Res. 189:206. PubMed
  22. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  23. Tsou WI, et al. 2014. J Biol Chem. 289:25750. PubMed
  24. Awojoodu AO, et al. 2014. Blood. 124:1941. PubMed
  25. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  26. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
Product Citations
  1. Yao Z, et al. 2018. J Virol. 92:00:00. PubMed
  2. Uriostegui–Arcos M, et al. 2020. Open Biol. 10:200050. PubMed
  3. Derudder E, et al. 2016. Proc Natl Acad Sci U S A. 113: 5065-5070. PubMed
  4. Zhang T, et al. 2022. EBioMedicine. 77:103872. PubMed
  5. Dhoonmoon A, et al. 2022. Nat Commun. 13:5063. PubMed
  6. Glynn RA, et al. 2022. J Immunol. 208:371. PubMed
  7. Cao H, et al. 2022. Br J Haematol. 198:155. PubMed
  8. Ugamraj HS, et al. 2022. MAbs. 14:2095949. PubMed
  9. Cao L, et al. 2022. Cell Rep. 40:111156. PubMed
  10. Choi UY, et al. 2022. Cell Rep. 40:111234. PubMed
  11. Kimmerling RJ, et al. 2022. Commun Biol. 5:1295. PubMed
  12. Chen X, et al. 2022. Front Pharmacol. 13:1028692. PubMed
  13. Shahid AM, et al. 2022. PLoS One. 17:e0278209. PubMed
  14. Önel T, et al. 2023. Naunyn Schmiedebergs Arch Pharmacol. :. PubMed
  15. Papakonstantinou A, et al. 2022. Int J Mol Sci. 24: . PubMed
  16. Li J, et al. 2023. J Biol Chem. 299:102875. PubMed
  17. Martinelli M, et al. 2023. iScience. 26:105860. PubMed
  18. Tay HG, et al. 2023. Mol Ther. 31:825. PubMed
  19. Dean BD, et al. 2023. J Immunother Cancer. 11: . PubMed
  20. Lieschke E, et al. 2022. Cell Death Differ. 29:1004. PubMed
  21. Gallego-Murillo JS, et al. 2022. Biotechnol Bioeng. 119:3096. PubMed
  22. Du X, et al. 2023. Nucleic Acids Res. 51:1050. PubMed
  23. Vanoli F, et al. 2023. Oncogenesis. 12:8. PubMed
  24. Lei K, et al. 2023. iScience. 26:106001. PubMed
  25. Ohuchi K, et al. 2023. Biomed Rep. 18:28. PubMed
  26. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  27. Perez GI, et al. 2023. Vaccines (Basel). 11:. PubMed
  28. Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed
  29. Potez M, et al. 2023. Front Oncol. 13:1124272. PubMed
  30. Woodley K, et al. 2023. Nat Commun. 14:2132. PubMed
  31. Quintela M, et al. 2023. Clin Epigenetics. 15:63. PubMed
  32. Quintela M, et al. 2023. Br J Cancer. . PubMed
  33. Lin, R. C., Shao, Z., et al. 2025. Front Immunol. 16(0),1641365. PubMed
  34. Monmai, C., Sabuakham, S., et al. 2025. Biomolecules. 15(10),0. PubMed
  35. Zheng, J., Zhou, J., et al. 2025. Commun Biol. 8(1),1562. PubMed
  36. Skrabanja, T. L. P., Klazen, J. A. Z., et al. 2025. STAR Protoc. 6(4),104204. PubMed
  37. Suwittayarak, R., Nowwarote, N., et al. 2025. Clin Exp Dent Res. 11(6),e70248. PubMed
  38. Xiang, Z., Wu, Y., et al. 2025. Zhejiang Da Xue Xue Bao Yi Xue Ban. 0(0),46031. PubMed
  39. Ortega, M., Agena, E., et al. 2025. Int J Mol Sci. 26(23),0. PubMed
  40. Giustarini, G., Skrabanja, T. L. P., et al. 2025. iScience. 28(12),114076. PubMed
  41. Megawati, E. R., Bangun, H., et al. 2025. Contemp Oncol (Pozn). 29(4),354-359. PubMed
  42. Vesal, M., Moazen Safaei, Y., et al. 2025. Pharmaceutics. 17(12),0. PubMed
  43. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  44. Dowling CM, et al. 2021. Sci Adv. 7:. PubMed
  45. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
  46. Kim EH, et al. 2020. Elife. 9:00. PubMed
  47. Kitayama J, et al. 2016. PLoS One. 11: 0154542. PubMed
  48. Gedye C, et al. 2016. Sci Rep. 6: 25220. PubMed
  49. Carlsson J, et al. 2015. PLoS One. 10: 0143741. PubMed
  50. Bouhaddou M, et al. 2018. PLoS Comput Biol. 14:e1005985. PubMed
  51. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  52. Yamauchi T et al. 2018. Cancer cell. 33(3):386-400 . PubMed
  53. Feng W, et al. 2017. Nat Commun. 0.697916667. PubMed
  54. Jones PD, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1711. PubMed
  55. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  56. Fujii T, et al. 2015. Proc Natl Acad Sci U S A. 112: 12800 - 12805. PubMed
  57. Cardoso B, et al. 2015. PLoS One. 10: 0143897. PubMed
  58. Alcon C, et al. 2020. Cell Death Dis. 0.898611111. PubMed
  59. Figueiredo T, et al. 2020. Mol Psychiatry. . PubMed
  60. Lopes-Coelho F, et al. 2021. Front Oncol. 11:656229. PubMed
  61. Wang Q, et al. 2022. Nat Commun. 13:3022. PubMed
  62. Olelewe C, et al. 2022. iScience. 25:104340. PubMed
  63. Kim Y, et al. 2020. J Neurochem. 155:177. PubMed
  64. Hassan MIA, et al. 2021. Comput Struct Biotechnol J. 19:880. PubMed
  65. Ramalingam P, et al. 2020. J Exp Med. 217:00:00. PubMed
  66. Bowen ME, et al. 2019. Dev Cell. 50:212. PubMed
  67. Sales–Dias J, et al. 2019. PLoS One. 14:e0217002. PubMed
  68. Santos LC, et al. 2019. Nat Commun. 1.328472222. PubMed
  69. Lim JA, et al. 2018. BMC Cancer. 0.860416667. PubMed
  70. Venter C, et al. 2017. Cell Physiol Biochem. 43:1288. PubMed
  71. Karavasili C, et al. 2017. International Journal of Pharmaceutics. 10.1016/j.ijpharm.2017.05.061. PubMed
  72. Thompson PJ et al. 2019. Cell metabolism. 29(5):1045-1060 . PubMed
  73. Noguchi F, et al. 2017. Mol Cancer Ther. 1.316666667. PubMed
  74. Kumar S, et al. 2018. Cancers (Basel). 0.724305556. PubMed
  75. Fortin J, et al. 2020. Cancer Cell. 37:308. PubMed
  76. Soprano M, et al. 2016. PLoS One. 11: 0155970. PubMed
  77. Macpherson L, et al. 2020. Nature. 577:266. PubMed
  78. Vereertbrugghen A, et al. 2021. Front Oncol. 11:598319. PubMed
  79. Sun V, et al. 2021. Front Immunol. 12:716661. PubMed
  80. Coray M, et al. 2022. Int J Mol Sci. 23:. PubMed
  81. Kim OV, et al. 2022. iScience. 25:104654. PubMed
  82. Shahzadi SK, et al. 2022. Clin Sci (Lond). 136:181. PubMed
  83. Kolbrink B, et al. 2022. Biochem J. 479:259. PubMed
  84. He C, et al. 2021. Oncoimmunology. 1897295:10. PubMed
  85. Pfalzgraff A, et al. 2016. Sci Rep. 6:31577. PubMed
  86. O'Neill K, et al. 2016. Genes Dev. 30: 973-988. PubMed
  87. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
  88. Vries M, et al. 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  89. Chen MS, et al. 2019. Mol Cancer Res. 17:697. PubMed
  90. Ni F, et al. 2019. Cell Stem Cell. 24:608. PubMed
  91. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  92. Greenblatt SM, et al. 2018. Cancer Cell. 33:1111. PubMed
  93. Naqvi N,et al. 2017. Sci Rep.. 10.1038/s41598-017-12753-1. PubMed
  94. Wang M, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.097. PubMed
  95. Beeravolu N, McKee C, Chaudhry G 2017. J App Toxicol. 10.1002/jat.3469. PubMed
  96. Esteghamat F, et al. 2019. Nat Genet. 51:1233. PubMed
  97. Blümel E, et al. 2020. Oncoimmunology. 9:1751561. PubMed
  98. Sekine C, et al. 2009. Int Immunol. 1.079861111. PubMed
  99. Parrula M, et al. 2014. Virus Res. 189:206. PubMed
  100. Brigger D, et al. 2015. Cell Death Dis. 6: e1861. PubMed
  101. Zhang J, et al. 2016. Cell Death Dis. 7:e2266. PubMed
  102. Wang D, et al. 2016. J Cell Sci. 129: 2261 - 2272. PubMed
  103. Uchtenhagen H, et al. 2016. Nat Commun. 7:12614. PubMed
  104. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  105. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  106. O'Connor MJ, et al. 2021. Oncogene. 40:4872. PubMed
  107. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  108. Martín Monreal MT, et al. 2021. Front Immunol. 12:716250. PubMed
  109. Schmitz RL, et al. 2021. Cells. 10:. PubMed
  110. Babaei A, et al. 2021. Adv Pharm Bull. 11:361. PubMed
  111. Madala HR, et al. 2020. Cancer Res. 3492:80. PubMed
  112. Clements KE, et al. 2020. Nat Commun. 4.706944444. PubMed
  113. Rauzan M, et al. 2017. PLoS One. 12:e0174107. PubMed
  114. Liu Y, et al. 2017. Acta Biomater. 10.1016/j.actbio.2017.08.021. PubMed
  115. Chiani M, et al. 2017. Artif Cells Nanomed Biotechnol. 10.1080/21691401.2017.1337029. PubMed
  116. Kamiyama N, et al. 2017. Antiviral Res. 10.1016/j.antiviral.2017.08.007. PubMed
  117. Montero–Herradón S, et al. 2017. Organogenesis. 0.675. PubMed
  118. Nunes SC, et al. 2018. Sci Rep. 6.939583333. PubMed
  119. Sharif T, et al. 2018. Autophagy. 1.101388889. PubMed
  120. Eichelmann AK, et al. 2018. Sci Rep. 8:17553. PubMed
  121. Blümel E, et al. 2019. Oncoimmunology. 8:e1641387. PubMed
  122. Salge-Bartels U, et al. 2014. Thromb Res. 133:244. PubMed
  123. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  124. Ligtenberg M, et al. 2016. J Immunol. 196: 759 - 766. PubMed
  125. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
  126. Herold N, et al. 2017. Nat Med. 23:256-263. PubMed
  127. Xie S, et al. 2021. Sci Rep. 0.660416667. PubMed
  128. Müller I, et al. 2020. Mol Cell. 970:77. PubMed
  129. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  130. Norkin M, et al. 2021. Cell Rep. 35:109026. PubMed
  131. Krauss PL, et al. 2021. Front Immunol. 12:730672. PubMed
  132. Zhu Y, et al. 2022. Clin Transl Med. 12:e887. PubMed
  133. Khatib JB, et al. 2022. Oncotarget. 13:1078. PubMed
  134. Matsuda K, et al. 2021. Cell Rep Methods. 1:100122. PubMed
  135. Vanoli F, et al. 2021. Oncogene. 40:5095. PubMed
  136. Liu H, et al. 2021. J Immunother Cancer. 9:. PubMed
  137. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  138. Li Y, et al. 2021. Sci Transl Med. 13:. PubMed
  139. Meyer N, et al. 2021. J Clin Med. 10:. PubMed
  140. Yoon Y, et al. 2016. Stem Cell Reports. 7:840-853. PubMed
  141. Chheda Z, et al. 2016. J Immunol. 197: 2016 - 2026. PubMed
  142. Slone E, et al. 2015. J Leukoc Biol. 98: 791 - 804. PubMed
  143. Séguier S, et al. 2013. PLoS One. 8:70937. PubMed
  144. Liu H, et al. 2020. Cell Death Dis. 0.767361111. PubMed
  145. Zervou S, et al. 2017. PLoS One.. 10.1371/journal.pone.0182994. PubMed
  146. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  147. Litzenburger UM, et al. 2017. Genome Biol. 18:15. PubMed
  148. Rajavel T, et al. 2017. Sci Rep. 2.665277778. PubMed
  149. Grujic M, et al. 2010. J Immunol. 185:1730. PubMed
  150. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  151. Douguet L, et al. 2016. PLoS One. 11:e0166164. PubMed
  152. Toutounchian J, et al. 2016. Mol Pharmacol. 91(1):1-13. PubMed
  153. Pajarillo E, et al. 2020. J Biol Chem. 295:3040. PubMed
  154. Gholamrezaei M, et al. 2021. Iran J Parasitol. 15:475. PubMed
  155. Meyer N, et al. 2021. Int J Mol Sci. 22:. PubMed
  156. Kolbrink B, et al. 2022. Cell Mol Life Sci. 79:387. PubMed
  157. Ishida M, et al. 2021. Int J Mol Sci. 22:. PubMed
  158. Lee DH, et al. 2020. Circ Res. 127:1182. PubMed
  159. Alsina-Sanchis E, et al. 2020. Mol Cancer Res. . PubMed
  160. L Chang, Y Li, D Kaplan 2016. Sci Rep. 6:36862. PubMed
  161. Becker A, et al. 2016. Sci Rep. 6: 33847. PubMed
  162. Kumai T, et al. 2015. Sci Rep. 5:16280. PubMed
  163. Polak R, et al. 2015. Blood. 126: 2404 - 2414. PubMed
  164. Matsumoto A, et al. 2019. J Extracell Vesicles. 9:1696517. PubMed
  165. Pirali T, et al. 2017. ChemMedChem. 1.570833333. PubMed
  166. Hafez A, et al. 2017. Oncogenesis. 10.1038/oncsis.2017.46. PubMed
  167. Putheti P, et al. 2010. PLoS One. 5:e8706. PubMed
  168. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  169. Tsou W, et al. 2014. J Biol Chem. 289:25750. PubMed
  170. Dhoonmoon A, et al. 2020. Nucleic Acids Res. 48:7252. PubMed
  171. Nastasi C, et al. 2021. Sci Rep. 11:1458. PubMed
  172. Molinar-Inglis O, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  173. Erdogan M, et al. 2022. Chem Biodivers. 19:e202200659. PubMed
  174. Shadboorestan A, et al. 2022. Iran J Basic Med Sci. 25:506. PubMed
  175. Huang Y, et al. 2022. Front Cell Dev Biol. 9:837777. PubMed
  176. Babaei A, et al. 2020. Daru. 28:555. PubMed
  177. King R, et al. 2021. Sci Adv. 7:eabj5293. PubMed
  178. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  179. Liu B, et al. 2016. J Biol Chem. 291: 23869 - 23881. PubMed
  180. Lhuillier C, et al. 2015. J Biol Chem. 290: 16797 - 16811. PubMed
  181. Passaro C, et al. 2013. Endocr Relat Cancer. 20:633. PubMed
  182. Mulik R, et al. 2010. Int J Pharm. 398:190. PubMed
  183. Speth C, et al. 2013. J Infect Dis. 207:823. PubMed
  184. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  185. Lee HW, et al. 2018. Am J Physiol Renal Physiol. 314:F280. PubMed
  186. Ki H, et al. 2017. Biomed Pharmacother. 10.1016/j.biopha.2017.09.118. PubMed
  187. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
  188. Di Somma S, et al. 2019. Cancers (Basel). 1.70625. PubMed
  189. Lin W, et al. 2014. PLoS One. 9:83160. PubMed
  190. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  191. CO L, et al. 2015. Nat Commun. 6: 7739. PubMed
  192. Huang YL, et al. 2020. Elife. 9:00. PubMed
  193. Abu El Maaty MA, et al. 2021. Sci Adv. 7: . PubMed
  194. Bahl S, et al. 2021. Cell Death Dis. 12:469. PubMed
  195. Jackson LM, et al. 2021. Nucleic Acids Res. 49:12855. PubMed
  196. Tatangelo V, et al. 2022. Front Oncol. 12:877495. PubMed
  197. Alcon C, et al. 2021. Cells. 10:. PubMed
  198. Cao H, et al. 2021. Nat Commun. 12:1792. PubMed
  199. Faria M, et al. 2017. PLoS One. 12(2):e0172689. PubMed
  200. Jones P, et al. 2016. J Biol Chem. 291: 16318 - 16327. PubMed
  201. Awojoodu A, et al. 2014. Blood. 124:1941. PubMed
  202. Intemann J, et al. 2014. Cell Signal. 26:1567. PubMed
  203. Labi V, et al. 2019. Genes Dev. 33:1673. PubMed
  204. Fang P, et al. 2019. Commun Biol. 0.315972222. PubMed
  205. Kumar S, et al. 2019. Int J Cancer. 146:1652. PubMed
  206. Zhao CC, et al. 2018. Oncol Rep. 40:3392. PubMed
  207. Schleicher EM, et al. 2018. Nucleic Acids Res. 46:8908. PubMed
  208. Thomas A, et al. 2017. PLoS One.. 10.1371/journal.pone.0183542. PubMed
  209. Clements KE, et al. 2018. Nucleic Acids Res. 46:8898. PubMed
  210. Bostanabad SY, et al. 2021. Sci Rep. 11:1539. PubMed
  211. Monzen S, et al. 2022. Mol Clin Oncol. 16:19. PubMed
  212. Konda P, et al. 2022. Am J Cancer Res. 12:210. PubMed
  213. Wu J, et al. 2021. Adv Sci (Weinh). 8:e2101029. PubMed
  214. Tu Z, et al. 2022. Cell Rep. 40:111072. PubMed
  215. Bensberg M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  216. Paparella AS, et al. 2021. Nat Commun. 12:6285. PubMed
  217. Huang YL, et al. 2021. iScience. 24:103168. PubMed
  218. Zhang Y, et al. 2021. Cell Death Dis. 0.563194444. PubMed
  219. Kang JH, et al. 2020. Cell Death Dis. 0.803472222. PubMed
  220. Dewdney B, et al. 2020. Sci Rep. 10:16769. PubMed
  221. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  222. Coutaz M, et al. 2016. Sci Rep. 6:39117. PubMed
  223. Akane K, et al. 2016. Proc Natl Acad Sci U S A. 113: 2460 - 2465. PubMed
  224. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  225. Chen Y, et al. 2013. J Exp Med. 210:2515. PubMed
  226. Mendès C, et al. 2019. Sci Rep. 9:14107. PubMed
  227. Lopes–Coelho F, et al. 2017. Oncotarget. 8:82803. PubMed
  228. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  229. Thanuthanakhun N, et al. 2017. PLoS One. . 10.1371/journal.pone.0187610. PubMed
  230. Kuntz E, et al. 2017. Nat Med. 10.1038/nm.4399. PubMed
  231. Siddhartha V, et al. 2017. Artif Cells Nanomed Biotechnol . 10.1080/21691401.2017.1313267. PubMed
  232. He J, et al. 2017. FASEB J. 31:2893. PubMed
  233. Lyu X, et al. 2019. BMC Genomics. 1.235416667. PubMed
  234. Jing Y, et al. 2019. J Allergy Clin Immunol. 144:1377. PubMed
  235. Quan M, et al. 2019. Oncol Rep. 41:3051. PubMed
  236. Bottardi S, et al. 2020. Exp Hematol. 68:88. PubMed
  237. Kasikara C, et al. 2021. J Clin Invest. 131:. PubMed
  238. Ning N, et al. 2022. Theranostics. 12:5537. PubMed
  239. Wang Y, et al. 2022. Front Cardiovasc Med. 9:876087. PubMed
  240. Shankman LS, et al. 2021. Curr Biol. 31:2469. PubMed
  241. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  242. Pahari S, et al. 2020. Autophagy. 1.375694444. PubMed
  243. Schleicher EM, et al. 2020. PLoS Genet. 16:e1009176. PubMed
  244. Langsch S, et al. 2016. Cancer Res . 76: 4160 - 4169. PubMed
  245. Xiong R, et al. 2015. Mol Pharmacol. 88: 1045 - 1054. PubMed
  246. Hellmann J, et al. 2013. J Immunol. 191:1383. PubMed
  247. Juel H, et al. 2013. PLoS One. 8:64619. PubMed
  248. Gill K, et al. 2013. Biochim Biophys Acta. 1830:2763. PubMed
  249. Young MM, et al. 2019. Cell Death Dis. 1.004861111. PubMed
  250. Santos I, et al. 2019. Nutrients. 2.210416667. PubMed
  251. Vancsik T, et al. 2019. Cancer Med. 3.313888889. PubMed
  252. Zheng M, et al. 2019. Proc Natl Acad Sci U S A. 116:12422. PubMed
  253. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
RRID
AB_2561291 (BioLegend Cat. No. 640905)
AB_2561292 (BioLegend Cat. No. 640906)
AB_2629519 (BioLegend Cat. No. 640945)

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
308 View all products for this Gene ID
UniProt
View information about Annexin V on UniProt.org

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 7    Revision Date: 10.22.2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account